EA
REGN icon

Everpar Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Everpar Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Sell
445
-98
-18% -$66.7K 0.08% 230
2026
Q1 		$420K Buy
543
+38
+8% +$29.1K 0.14% 152
2025
Q4 		$390K Sell
505
-112
-18% -$76.1K 0.14% 157
2025
Q3 		$347K Buy
617
+100
+19% +$56.5K 0.14% 174
2025
Q2 		$271K Buy
517
+71
+16% +$39.6K 0.12% 213
2025
Q1 		$283K Sell
446
-34
-7% -$23.4K 0.15% 193
2024
Q4 		$342K Sell
480
-113
-19% -$94.8K 0.17% 165
2024
Q3 		$623K Sell
593
-229
-28% -$255K 0.32% 78
2024
Q2 		$864K Buy
822
+133
+19% +$129K 0.43% 51
2024
Q1 		$663K Sell
689
-201
-23% -$191K 0.4% 71
2023
Q4 		$782K Buy
+890
New +$733K 0.36% 97

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Everpar Advisors's REGN Position: Q2 2026 in Review

Everpar Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, selling an estimated $66.7K and leaving 445 shares worth $277K. The position accounts for 0.08% of the portfolio, ranked #230.

Everpar Advisors first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $864K in Q2 2024. 180 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Everpar Advisors held 445 shares of Regeneron Pharmaceuticals worth $277K as of Q2 2026.
  • Everpar Advisors sold 98 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $66.7K.
  • Regeneron Pharmaceuticals made up 0.08% of Everpar Advisors's portfolio in Q2 2026, its #230 holding.
  • Everpar Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Everpar Advisors's Regeneron Pharmaceuticals position peaked at $864K in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Everpar Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.